Navigation Links
Geisinger Partners With Indivumed for Personalized Medicine Initiative

DANVILLE, Pennsylvania, May 10, 2013 /PRNewswire/ --

Geisinger Health System announced plans to partner with Indivumed, a leading provider of services enabling individualized cancer therapy, a relationship that will afford Geisinger patients access to advanced cancer treatment and clinical trials.

"Our driving mission for nearly 100 years comes from a simple mandate, 'Make it the best,'" said Glenn D. Steele Jr. , M.D., Ph.D., president and chief executive officer at Geisinger Health System. "This exciting initiative with Indivumed, a company recognized the world over as a leader in the field of biobanking and translational research, will give Geisinger patients access to the most advanced cancer therapeutics in the country, right here in central and northeastern Pennsylvania."

The collaboration will allow Indivumed staff to collect tissue, blood and urine from consenting Geisinger patients who are already undergoing a surgical tumor resection. Upon resection, a portion of the tissue, blood or urine remaining beyond what is required to make a clinical diagnosis will be banked by Geisinger through MyCode™, a repository that currently holds 43,000 patient samples. Another portion will be banked by Indivumed, which will analyze the tissue to determine its molecular and biochemical profile. That information will be used in the development and, eventually, application of targeted therapies for cancer patients.

"A comprehensive analysis of patient's individual cancers including DNA sequencing, determination of protein expression and activity of therapy relevant cancer pathways is the foundation of personalized cancer treatment," said Hartmut Juhl , M.D., chief executive officer of Indivumed. "Understanding that the donation of tissue is a deeply personal one, our work is conducted under stringent quality standards and with great care in order to quickly translate new scientific discoveries into the practice of medicine.

Based in Hamburg, Germany, Indivumed is an integrated oncology company that leverages its biorepository of human tissue samples with its diagnostic laboratory to develop individualized cancer therapies. While Indivumed is focused on tissue testing, its subsidiary Inostics is analyzing circulating tumor DNA in plasma to determine therapy relevant cancer mutations and to monitor disease. The overall goal is understanding the biological differences between tumors and how patients respond to treatments to support the implementation of personalized therapy. To this end, Indivumed maintains a biobank of tissues and annotated data from about 17,000 patients - with about 1,500 new cases added per year - each collected under exactly defined specifications.

Research demonstrates that proteins change expression profiles significantly within minutes following surgical resection. Many of those proteins might serve as biomarkers for new drugs. Therefore, controlled and rapid tissue processing is necessary for understanding biological differences of or within patient tumors, especially when developing targeted therapies. Indivumed follows highly standardized processes that enable the company to limit cold ischemia time - the time between removal of tissue from the body and the time it is preserved - to less than 10 minutes, guaranteeing tissue samples maintain their biological integrity.

"The goal of this collaboration is to translate genetic and proteomic data into specific knowledge about a disease that is clinically relevant and will enhance patient care," Dr. Steele said. "We continually strive to look for innovative opportunities to provide patients with the most advanced care modern science has to offer."

About Geisinger Health System

Geisinger Health System is an integrated health services organization widely recognized for its innovative use of the electronic health record, and the development of innovative care models such as ProvenHealth Navigator® and ProvenCare®. As the nation's largest rural health services organization, Geisinger serves more than 2.6 million residents throughout 44 counties in central and northeastern Pennsylvania. The physician-led system is comprised of more than 20,000 employees, including a 1,000-member multi-specialty group practice, six hospital campuses, two research centers and the 400,000-member Geisinger Health Plan, all of which leverage an estimated $5.5 billion positive impact on the Pennsylvania economy. The health system and the health plan have repeatedly garnered national accolades for integration, quality and service. In addition to fulfilling its patient care mission, Geisinger has a long-standing commitment to medical education, research and community service. For more information, visit, or follow the latest Geisinger news and more on Twitter and Facebook.

About Indivumed

Indivumed is a privately held biotech company focused on the generation, characterization and analysis of highly standardized biological samples from human cancer. Founded in 2002 and headquartered in Hamburg, Germany, with a subsidiary in Baltimore, MD, USA, Indivumed has cooperation agreements with all major oncological hospitals in the Hamburg metropolitan area, Germany, as well as with Georgetown University Hospital, and the Washington Hospital Center in Washington, DC. Indivumed's current tumor biobank of over 17,000 patient-cases, collected with a mean cold ischemia time of less than ten minutes, serves as a resource for Indivumed's internal cancer research in biomarkers and primary cell drug screening as well as for the use of pharmaceutical and biopharma partners through tumor biobank access and a variety of services, such as e.g. Immunohistochemistry, phosphoprotein analysis and drug profiling.

Together with its subsidiary Inostics, which was founded by Indivumed and scientists from Johns Hopkins University in Baltimore, MD, Indivumed translates scientific knowledge to the benefit of cancer patients.

Amanda O'Rourke : +1-570-214-9091

SOURCE Indivumed GmbH
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. TeleTracking Announces Real-Time Locating System (RTLS) Contract with Geisinger Health
2. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
3. Fuse Science Partners With GNC To Open National Distribution Of EnerJel™
4. Medical Guardian Announces Social Media Partnership with Senior Citizen Charity
5. The ALS Therapy Development Institute Partners with Neurotune to Investigate Potential Treatments for Motor Neuron Disease
6. ClearCanvas Partners With DPR to Offer CaseReader™, an Integrated Technology Structured Reporting Solution for Medical Imaging Professionals
7. VitaTech Adds New Capacity for Production and Customer Interface, Attributes Growth to Strategic Customer Partnerships
8. Bayer Partnership Delivers Industry-First Dose Management Offering
9. HUYA Bioscience International Engages In Partnership With Zhuhai Sanzao Science and Technology Industrial Park
10. Profil Institute Partners with Florida Hospital to Establish East Coast Center for Clinical Metabolic Research
11. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
Post Your Comments:
(Date:11/27/2015)... YORK , November 27, 2015 ... system is set to go online. The potential to ... processes is vast and far from fully exploited as ... to patient health records, either via mobile tablet or ... ) --> ) --> ...
(Date:11/27/2015)... ) ... "2016 Global Tumor Marker Testing Market: Supplier ... Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive ... offering. --> ) has ... Global Tumor Marker Testing Market: Supplier Shares ...
(Date:11/26/2015)... Netherlands , November 26, 2015 ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... Netherlands has found that immunotherapy can be ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end ... Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you ... for not only fulfilling the needs of advisers and clients but going above ... and providing top-tier customer service. However, there's always room for improvement, which is ...
(Date:11/27/2015)... ... , ... CBD College is proud to announce that on November ... to its Diagnostic Medical Sonography program. CBD College is honored to join this very ... and universities in the state of California make the cut. CBD College is officially ...
(Date:11/27/2015)... ... , ... Dr. Thomas Dunlap and Dr. Patrick Coleman , ... Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial Hospital , co-hosted ... similar ways and require time-critical intervention to avoid large area heart damage and progressive ...
(Date:11/27/2015)... ... 27, 2015 , ... Indosoft Inc., developer and distributor of ... 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making ... with a version of Asterisk that will receive not only security fixes, but ...
Breaking Medicine News(10 mins):